Navigation Links
GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology
Date:4/19/2011

VICTORIA, Australia, April 19, 2011 /PRNewswire/ -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has executed a preliminary research collaboration agreement to jointly develop a new cancer profiling product with one of the world's leading pharmaceutical companies.

Under the collaboration Genetic Technologies will use certain expertise and intellectual property to work with this world-leading pharmaceutical company to develop specific and novel genetic oncology profiling systems for the targeting of chemotherapy in late stage cancer patients.

GTG will collaborate in a clinical oncology study and provide these results to its collaboration partner. The details of the collaboration and the identity of the counterparty are confidential. This stage of the project is expected to last some months after which time the parties will assess progress and discuss moving to further investigations.

Genetic Technologies' Chief Executive Officer Dr Paul MacLeman said: "GTG's expertise in genetic profiling is widely respected. This collaboration is a validation of GTG's capabilities in the area of very low signal to noise nucleic acid analysis, and we look forward to working with one of the most successful pharmaceutical companies in the world."

"This research collaboration is expected to further embed GTG's franchise in oncology testing and we expect ultimately to lead to better patient outcomes. The need for companion diagnostics to determine effective treatments for cancer patients is well established. We are very excited by this collaboration as we continue to expand our presence in the field of personalized medicine."

About Genetic Technologies LimitedGenetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid).  The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species.  Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.

Safe Harbor StatementAny statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genesis Bioventures' business can be found in its periodic filings with the SEC.ENQUIRIESDr Paul D R MacLeman

Rudi Michelson (Australia)

Seth Lewis (USA)Chief Executive Officer

Monsoon Communications

Trout Group Inc.Genetic Technologies Limited

(03) 9620 3333

(646) 378 2952Phone: +61 3 8412 7000
'/>"/>

SOURCE Genetic Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart Announces Closing of $50 Million Series G Financing
2. MiMedx Group, Inc. Announces Release Date for First Quarter Results
3. Awarepoint Corporation Announces Acquisition of PCTS
4. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
5. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
6. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
7. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
8. American Scientific Resources, Inc. Announces Corporate Update
9. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
10. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
11. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... -- With opioids commonly used for pain management for workplace injuries, ... has led to nationwide fatalities. The synthetic opioid called ... heroin or morphine, resulting in likelihood of addiction, abuse or death. ... , , ... Behavioral Health for HMC HealthWorks, explained the opioid drug is less ...
(Date:12/6/2016)... new study released today by the Alliance for ... Drug Pricing Program will continue to expand at an unprecedented ... exceed $23 billion in total purchases at the 340B price. ... Part B drug reimbursement purchases over the next five years. ... of data on total drug purchases through 340B from 2005 ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... , ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration ... to America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy ... country. , Nancy attributes her patriotic nature to her WWII veteran father. She ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ... cerebral cavernous angiomas, was awarded a grant from the Julian Grace Foundation to ... Mexico has more people with cavernous angioma than anywhere in the world. Most ...
(Date:12/7/2016)... ... , ... NuevaCare, a leading home care agency based in San Mateo but ... as part of its ambitious website relaunch. As Bay Area clients scramble to find ... serving their city. The new site has several key city-specific pages to address this ...
(Date:12/6/2016)... ... 06, 2016 , ... The International Vaccine Institute (IVI) and ... the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine ... deployment in the event of a future outbreak. , IVI and GeneOne held ...
(Date:12/6/2016)... ... December 06, 2016 , ... According to a November ... such as consuming too many mints or not drinking enough water, which can cause ... California Dental Care notes that good oral hygiene not only helps reduce the possibility ...
Breaking Medicine News(10 mins):